These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 34357095)

  • 1. Effect of Tocilizumab in Reducing the Mortality Rate in COVID-19 Patients: A Systematic Review with Meta-Analysis.
    Conti V; Corbi G; Sellitto C; Sabbatino F; Maci C; Bertini N; De Bellis E; Iuliano A; Davinelli S; Pagliano P; Filippelli A
    J Pers Med; 2021 Jul; 11(7):. PubMed ID: 34357095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL-6 serum levels predict severity and response to tocilizumab in COVID-19: An observational study.
    Galván-Román JM; Rodríguez-García SC; Roy-Vallejo E; Marcos-Jiménez A; Sánchez-Alonso S; Fernández-Díaz C; Alcaraz-Serna A; Mateu-Albero T; Rodríguez-Cortes P; Sánchez-Cerrillo I; Esparcia L; Martínez-Fleta P; López-Sanz C; Gabrie L; Del Campo Guerola L; Suárez-Fernández C; Ancochea J; Canabal A; Albert P; Rodríguez-Serrano DA; Aguilar JM; Del Arco C; de Los Santos I; García-Fraile L; de la Cámara R; Serra JM; Ramírez E; Alonso T; Landete P; Soriano JB; Martín-Gayo E; Fraile Torres A; Zurita Cruz ND; García-Vicuña R; Cardeñoso L; Sánchez-Madrid F; Alfranca A; Muñoz-Calleja C; González-Álvaro I;
    J Allergy Clin Immunol; 2021 Jan; 147(1):72-80.e8. PubMed ID: 33010257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beneficial and harmful outcomes of tocilizumab in severe COVID-19: A systematic review and meta-analysis.
    Rubio-Rivas M; Forero CG; Mora-Luján JM; Montero A; Formiga F; Homs NA; Albà-Albalate J; Sánchez L; Rello J; Corbella X
    Pharmacotherapy; 2021 Nov; 41(11):884-906. PubMed ID: 34558742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tocilizumab as treatment for COVID-19: A systematic review and meta-analysis.
    Petrelli F; Cherri S; Ghidini M; Perego G; Ghidini A; Zaniboni A
    World J Methodol; 2021 May; 11(3):95-109. PubMed ID: 34026583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tocilizumab in the treatment of COVID-19-a meta-analysis.
    Avni T; Leibovici L; Cohen I; Atamna A; Guz D; Paul M; Gafter-Gvili A; Yahav D
    QJM; 2021 Nov; 114(8):577-586. PubMed ID: 34010403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addition of Tocilizumab to the Standard of Care Reduces Mortality in Severe COVID-19: A Systematic Review and Meta-Analysis.
    Boregowda U; Perisetti A; Nanjappa A; Gajendran M; Kutti Sridharan G; Goyal H
    Front Med (Lausanne); 2020; 7():586221. PubMed ID: 33123544
    [No Abstract]   [Full Text] [Related]  

  • 7. The Use of Tocilizumab in Patients with COVID-19: A Systematic Review, Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Studies.
    Maraolo AE; Crispo A; Piezzo M; Di Gennaro P; Vitale MG; Mallardo D; Ametrano L; Celentano E; Cuomo A; Ascierto PA; Cascella M
    J Clin Med; 2021 Oct; 10(21):. PubMed ID: 34768455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and harms of tocilizumab for the treatment of COVID-19 patients: A systematic review and meta-analysis.
    Piscoya A; Parra Del Riego A; Cerna-Viacava R; Rocco J; Roman YM; Escobedo AA; Pasupuleti V; White CM; Hernandez AV
    PLoS One; 2022; 17(6):e0269368. PubMed ID: 35657993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy of IL-6 inhibitor Tocilizumab in reducing severe COVID-19 mortality: a systematic review.
    Kaye AG; Siegel R
    PeerJ; 2020; 8():e10322. PubMed ID: 33194450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased Mortality in Coronavirus Disease 2019 Patients Treated With Tocilizumab: A Rapid Systematic Review and Meta-analysis of Observational Studies.
    Malgie J; Schoones JW; Pijls BG
    Clin Infect Dis; 2021 Jun; 72(11):e742-e749. PubMed ID: 32964913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of tocilizumab in the management of COVID-19: a systematic review and meta-analysis of observational studies.
    Viswanatha GL; Anjana Male CKVLSN; Shylaja H
    Clin Exp Rheumatol; 2022 Mar; 40(3):634-646. PubMed ID: 34251307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tocilizumab: An Effective Therapy for Severely and Critically Ill COVID-19 Patients.
    Bhandari S; Rankawat G; Singh A
    Indian J Crit Care Med; 2021 Mar; 25(3):260-266. PubMed ID: 33790504
    [No Abstract]   [Full Text] [Related]  

  • 13. [Early use of tocilizumab in hospitalized patients with severe and critical COVID-19 in the Province of Buenos Aires: a multicentric study].
    Salazar M; Varela Baino AN; González S; González Martínez V; Varela T; Regairaz L; Torres K; Kreplak N; Estenssoro E
    Medicina (B Aires); 2023; 83(2):190-201. PubMed ID: 37094187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo COvid19 REgistry (SMACORE).
    Colaneri M; Bogliolo L; Valsecchi P; Sacchi P; Zuccaro V; Brandolino F; Montecucco C; Mojoli F; Giusti EM; Bruno R; The Covid Irccs San Matteo Pavia Task Force
    Microorganisms; 2020 May; 8(5):. PubMed ID: 32397399
    [No Abstract]   [Full Text] [Related]  

  • 15. Date of Admission during COVID-19 Pandemic Impacted Patient Outcomes in Addition to the Higher Efficacy of Tocilizumab Plus High-Dose Corticosteroid Therapy Compared to Tocilizumab Alone.
    Belhassen-García M; Sánchez-Puente A; Dorado-Díaz PI; López-Bernús A; Sampedro-Gómez J; Azibeiro-Melchor R; Marcano-Millán E; Rodríguez-Alonso B; Sánchez-Barrado ME; Hernández-García I; Madruga I; Hernández-Pérez G; Carbonell C; García-Aparicio J; Burgos L; López-Sánchez E; Reina C; Ramón AM; Cestero-Ramírez L; Boumhir F; Encinas-Sánchez D; Sánchez-Ledesma M; Herráez J; Araoz P; Sánchez-Crespo MJ; Rodríguez-Rodríguez S; Rodríguez-Gude AE; Sánchez-Hernández MV; Borrás R; Sagredo-Meneses V; Sánchez PL; Marcos M; Martín-Oterino JÁ
    J Clin Med; 2021 Dec; 11(1):. PubMed ID: 35011938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of Tocilizumab with and without Dexamethasone in Patients with Severe COVID-19: A Retrospective Study.
    Zarębska-Michaluk D; Jaroszewicz J; Rogalska M; Martonik D; Pabjan P; Berkan-Kawińska A; Bolewska B; Oczko-Grzesik B; Kozielewicz D; Tudrujek-Zdunek M; Kowalska J; Moniuszko-Malinowska A; Kłos K; Rorat M; Leszczyński P; Piekarska A; Polańska J; Flisiak R
    J Inflamm Res; 2021; 14():3359-3366. PubMed ID: 34295173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study.
    Moreno-Pérez O; Andres M; Leon-Ramirez JM; Sánchez-Payá J; Rodríguez JC; Sánchez R; García-Sevila R; Boix V; Gil J; Merino E
    J Autoimmun; 2020 Nov; 114():102523. PubMed ID: 32690352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baricitinib in hospitalised patients with COVID-19: A meta-analysis of randomised controlled trials.
    Selvaraj V; Finn A; Lal A; Khan MS; Dapaah-Afriyie K; Carino GP
    EClinicalMedicine; 2022 Jul; 49():101489. PubMed ID: 35677732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of Tocilizumab in COVID-19: A Systematic Review and Meta-Analysis of Current Evidence.
    Kotak S; Khatri M; Malik M; Malik M; Hassan W; Amjad A; Malik F; Hassan H; Ahmed J; Zafar M
    Cureus; 2020 Oct; 12(10):e10869. PubMed ID: 33178522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular safety of tocilizumab: A systematic review and network meta-analysis.
    Castagné B; Viprey M; Martin J; Schott AM; Cucherat M; Soubrier M
    PLoS One; 2019; 14(8):e0220178. PubMed ID: 31369575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.